2X Match My Gift
This National Cancer Survivors Month, your gift is matched to expand treatment options and bring more patients into survivorship through Project Cure CRC.


Cookies4Chris, an annual Pittsburgh-area fundraiser benefiting the Colorectal Cancer Alliance and the University of Pittsburgh Medical Center, followed a different recipe this year.
The event, which has been a luncheon for the past eight years, became an evening gala this year and honored co-founder Marietta Barrett, who passed away in December.
Marietta was first a friend and then sister-in-law to Chris Sapienza, the event’s namesake and mother of Alliance CEO Michael Sapienza. Chris died from colon cancer in 2009.
This year’s Cookies4Chris was organized by an incredible volunteer committee led by Karla Sartori, Cathy Tannenholz, and Tabitha Cavanaugh.
With attendees’ generosity, Cookies4Chris raised nearly $20,000 this year for efforts to end colorectal cancer.
“I am full of gratitude for the allies who took responsibility for and supported Cookies4Chris after my aunt Marietta passed, ensuring this event continues to positively impact Pittsburgh and honor my mom’s memory,” Sapienza said .
The event, held May 23 at South Hills Country Club, included a seated dinner, silent auction, vendors, and the famous Pittsburgh cookie table.
Signature sponsors were UPMC, Frank Sapienza and Diane Hornyak, Michael Sapienza and Nathan Mattson, Dean Honda, Harolds Flowers, and Treasure Hunt.

The "Proud Supporter of the Colorectal Cancer Alliance" emblem is a high-resolution PNG graphic that anyone supporting the Alliance's mission to end colorectal cancer can display — digitally or in print.

When Helen was diagnosed with metastatic colorectal cancer, the biggest concern for her medical team was that her cancer had spread to her liver. One type of therapy, hepatic artery infusion, offered a path forward, but there was a catch. Nobody at her hospital had ever done it before. She'd have to be first.

Clinical trials can be life-changing. Learn how Kevin's participation in a Dana-Farber trial is helping him monitor colorectal cancer recurrence — and what it could mean for others.